CytomX Therapeutics (NASDAQ: CTMX) adds Charles Fuchs to board, grants options
Rhea-AI Filing Summary
CytomX Therapeutics, Inc. appointed Charles Fuchs, M.D., M.P.H., to its Board of Directors as a Class II director, effective July 24, 2026, with an initial term running until the company’s 2029 annual meeting of stockholders. He will receive the company’s standard non-employee director compensation.
Upon joining the board, Dr. Fuchs was granted an option to purchase 118,000 shares of common stock under the 2015 Equity Incentive Plan, with an exercise price equal to the closing price on July 24, 2026. The option vests as to 1/36th of the shares each month, subject to his continued service. The company will also enter into its standard indemnification agreement with him and states there are no related-party transactions over $120,000 or special arrangements connected to his appointment.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Director appointment date: July 24, 2026
Stock options granted: 118,000 shares
Monthly vesting fraction: 1/36th of shares
+1 more
4 metrics
Director appointment date
July 24, 2026
Effective date of Charles Fuchs’s appointment to the Board of Directors
Stock options granted
118,000 shares
Option to purchase common stock under the 2015 Equity Incentive Plan
Monthly vesting fraction
1/36th of shares
Portion of the option vesting on each monthly anniversary of appointment
Initial director term end
2029 annual meeting of stockholders
Scheduled end of initial term as a Class II director
Key Terms
Class II director, 2015 Equity Incentive Plan, non-employee director compensation, indemnification agreement
4 terms
Class II director regulatory
"appointed to the Board of Directors ... as a Class II director"
A class II director is a member of a company’s board who belongs to one of several staggered groups of directors, each group standing for election in different years. For investors, this matters because staggered terms slow wholesale board turnover—like rotating members of a neighborhood committee—making sudden changes in control or strategy harder and affecting how quickly shareholders can influence corporate direction.
2015 Equity Incentive Plan financial
"received an option under the Company’s 2015 Equity Incentive Plan"
non-employee director compensation financial
"Dr. Fuchs will receive the Company’s standard non-employee director compensation"
indemnification agreement regulatory
"the Company will enter into an indemnification agreement with Dr. Fuchs"
An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What board change did CytomX Therapeutics (CTMX) report on July 24, 2026?
CytomX Therapeutics appointed Charles Fuchs, M.D., M.P.H., to its Board of Directors as a Class II director, effective July 24, 2026. His initial term extends until the company’s 2029 annual meeting of stockholders, and he will receive standard non-employee director compensation.
How long is Charles Fuchs’s initial board term at CytomX Therapeutics (CTMX)?
Charles Fuchs’s initial term as a Class II director runs until CytomX’s 2029 annual meeting of stockholders. After that meeting, he would be subject to stockholder election in line with the company’s classified board structure and governance practices described for Class II directors.
What equity award did CytomX Therapeutics (CTMX) grant to Charles Fuchs?
Upon appointment, Charles Fuchs received an option for 118,000 shares of CytomX common stock under the 2015 Equity Incentive Plan. The exercise price equals the closing stock price on July 24, 2026, and the option vests in 1/36th monthly installments, subject to continued service.
How do Charles Fuchs’s stock options at CytomX Therapeutics (CTMX) vest?
The option to purchase 118,000 shares vests as to 1/36th of the shares on each monthly anniversary of his July 24, 2026 appointment. Vesting is conditioned on his continued service to CytomX through each applicable vesting date during the three-year vesting period.
Will CytomX Therapeutics (CTMX) enter an indemnification agreement with Charles Fuchs?
CytomX will enter into its standard indemnification agreement with Charles Fuchs, consistent with existing practice for directors. The form of this agreement was previously approved by the board and filed as Exhibit 10.16 to the company’s Form S-1 dated August 28, 2015.